Sutro Biopharma (FRA:S09) EV-to-EBIT : 0.31 (As of Jun. 22, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sutro Biopharma's Enterprise Value is €-19.6 Mil. Sutro Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-62.6 Mil. Therefore, Sutro Biopharma's EV-to-EBIT for today is 0.31.

The historical rank and industry rank for Sutro Biopharma's EV-to-EBIT or its related term are showing as below:

FRA:S09' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.33 Med: -1.89 Max: 30.94
Current: 0.31

During the past 8 years, the highest EV-to-EBIT of Sutro Biopharma was 30.94. The lowest was -27.33. And the median was -1.89.

FRA:S09's EV-to-EBIT is ranked better than
85.62% of 438 companies
in the Biotechnology industry
Industry Median: 8.76 vs FRA:S09: 0.31

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sutro Biopharma's Enterprise Value for the quarter that ended in Mar. 2024 was €53.1 Mil. Sutro Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-62.6 Mil. Sutro Biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -117.90%.

Sutro Biopharma EV-to-EBIT Historical Data

The historical data trend for Sutro Biopharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma EV-to-EBIT Chart

Sutro Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-2.84

-23.16

-5.36

-1.59

1.24

Sutro Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-0.39	0.51	0.68	1.24	-1.01

Competitive Comparison of Sutro Biopharma's EV-to-EBIT

For the Biotechnology subindustry, Sutro Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sutro Biopharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's EV-to-EBIT falls into.

Sutro Biopharma EV-to-EBIT Calculation

Sutro Biopharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-19.571	/	-62.569
	=	0.31

Sutro Biopharma's current Enterprise Value is €-19.6 Mil.
Sutro Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-62.6 Mil.

Sutro Biopharma (FRA:S09) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sutro Biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-62.569	/	53.06883
	=	-117.90 %

Sutro Biopharma's Enterprise Value for the quarter that ended in Mar. 2024 was €53.1 Mil.
Sutro Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-62.6 Mil.

Sutro Biopharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sutro Biopharma (FRA:S09) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

STRO:USA S09:Germany

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.sutrobio.com

Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma (FRA:S09) Headlines

No Headlines